Aptevo Therapeutics Reports Second Quarter 2017 Financial Results
August 10, 2017 09:02 ET
|
Aptevo Therapeutics
Showcases Differentiating Features of the ADAPTIR™Protein Therapeutic Platform at Prominent Industry Conferences Signs Collaboration Agreement with Alligator Bioscience Expanding Aptevo’s Portfolio...
Aptevo Therapeutics and Alligator Bioscience Announce Plans to Co-Develop Novel Bispecific Antibody for Tumor-Directed Immunotherapy
July 20, 2017 17:19 ET
|
Aptevo Therapeutics
Strategic Partnership Will Advance Development of a Novel BispecificImmuno-Oncology Antibody Targeting Compelling Biological PathwayImplicated in Multiple Solid Tumor Indications Focuses on New...
Aptevo Therapeutics Highlights Key Features of Its ADAPTIR™ Protein Therapeutic Platform at Two Industry Conferences
June 07, 2017 09:02 ET
|
Aptevo Therapeutics
SEATTLE, June 07, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today...
Aptevo Therapeutics Reports First Quarter 2017 Financial Results
May 12, 2017 09:02 ET
|
Aptevo Therapeutics
Expands ADAPTIR Portfolio and Announces New Bispecific Candidate; Presents Data at the 2016 PEPTALK Conference Showcasing Advantages of the ADAPTIR™ Platform SEATTLE, May 12, 2017 (GLOBE NEWSWIRE)...
Aptevo Therapeutics Presents Detailed Overview of its Adaptir™ Protein Therapeutic Platform at the 13th Annual Pegs Summit
May 05, 2017 09:02 ET
|
Aptevo Therapeutics
Key Advantages of the ADAPTIR Platform Showcased During the ‘Bispecific Antibodies in Oncology’ Session SEATTLE, May 05, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a...
Aptevo Therapeutics Presents New Clinical Data Evaluating the Safety and Efficacy of IXINITY in Children With Hemophilia B
April 10, 2017 09:00 ET
|
Aptevo Therapeutics
Data Presented at the Hemostasis and Thrombosis Research Society 2017 Scientific SymposiumSEATTLE, April 10, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology...
Aptevo Therapeutics’ Next Generation ADAPTIR™ Bispecific Antibody Candidates Show Potent Immune Activation
April 03, 2017 09:03 ET
|
Aptevo Therapeutics
New Preclinical Data Presented at the 2017 American Association for Cancer Research Annual Meeting Demonstrate Antibody-like Characteristics and Efficacy of Redirected T-Cell Cytotoxicity...
Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update
March 31, 2017 09:00 ET
|
Aptevo Therapeutics
Advances Multiple Clinical and Preclinical Candidates Based on the Company’s Novel ADAPTIR™ Protein Therapeutic Platform Achieves 30% Increase in Year-Over-Year Product Sales Revenue SEATTLE,...
Aptevo Therapeutics Announces New IXINITY Supply Available May 2017
March 15, 2017 08:30 ET
|
Aptevo Therapeutics
SEATTLE, March 15, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the...
Aptevo Therapeutics Expands Bispecific Antibody Portfolio
March 14, 2017 09:25 ET
|
Aptevo Therapeutics
SEATTLE, March 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that...